miR-302b has been reported to enhance breast cancer cell sensitivity to cisplatin by regulating ATM, which is an important serine/threonine kinase that transduces DNA damage signals to downstream effectors in the DNA damage response [69]. The gene discussed is MARK2; the disease is breast cancer.